Tazemetostat for Solid Cancers
Trial Summary
What is the purpose of this trial?
The FDA approved targeted agent tazemetostat inhibits EZH2 and induces durable tumor responses in patients with B-cell non-Hodgkin's lymphoma and epithelioid sarcomas. Responses have also been demonstrated in INI1 and SMARCA4 negative solid tumors patients. Since EZH2 plays a critical role in driving the biology of ARID1A mutated malignancies, we hypothesize that inhibition of EZH2 with tazemetostat will lead to significant clinical benefit in ARID1A mutated malignancies.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot take medications that are known potent CYP3A4 inducers/inhibitors, like St. John's wort. There are also specific time requirements between prior anticancer therapies and starting the trial drug.
What data supports the idea that Tazemetostat for Solid Cancers is an effective drug?
The available research does not provide specific data on Tazemetostat for Solid Cancers. Instead, it discusses other treatments like Serdemetan, Tiragolumab, and Pemetrexed for various types of cancers. Without specific data on Tazemetostat, we cannot determine its effectiveness compared to these other treatments.12345
What safety data is available for Tazemetostat in treating solid cancers?
The provided research does not contain specific safety data for Tazemetostat or its other names. The studies mentioned focus on different compounds and their effects on various cancer types, but none of them evaluate Tazemetostat. For safety data on Tazemetostat, it would be necessary to look for studies or clinical trials specifically involving Tazemetostat or its synonyms.678910
Research Team
Ki Chung, MD
Principal Investigator
Prisma Health
Eligibility Criteria
This trial is for adults with advanced or metastatic solid tumors that have an ARID1A mutation, excluding those with epithelioid sarcoma. Participants must have tried other treatments without success and should not be pregnant, breastfeeding, or have had major surgery recently. They need to be able to take oral medication and not have a history of certain cancers or severe heart conditions.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tazemetostat 800 mg orally twice daily in continuous 28-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Tazemetostat
Tazemetostat is already approved in United States, European Union for the following indications:
- Epithelioid sarcoma
- Follicular lymphoma
- Epithelioid sarcoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Prisma Health-Upstate
Lead Sponsor
Ipsen
Industry Sponsor
David Loew
Ipsen
Chief Executive Officer since 2020
BA in Business Administration and MBA from the University of St. Gallen, Switzerland
Sandra Silvestri
Ipsen
Chief Medical Officer since 2023
MD, PhD
Epizyme, Inc.
Industry Sponsor